Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant long-term safety extension in pediatric migraine
NCT05707949Phase 3Enrolling by invitation
- Sponsor
- AbbVie Inc.
- Start
- Jun 2023
- Primary completion
- Apr 2032
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, open-label trial of atogepant in migraine (2 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants with Adverse Events at 56 weeks, Percentage of Participants with Potentially Clinically Significant Lab Values at 52 weeks and 6 more. Started Jun 2023; status: enrolling by invitation.
02
Drugs
atogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05707949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05707949.